Showing results (1221-1230 of 1,364) with videos related to

Sort By:
Pageof 137
Epilepsia|August 6, 2023
Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trialJoseph Sullivan, Lieven Lagae, J Helen Cross, et al.
Journal for Immunotherapy of Cancer|March 21, 2019
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinomaMadelyn Espinosa-Cotton, Samuel N Rodman Iii, Kathleen A Ross, et al.
Journal of Psychiatric Research|June 10, 2009
Attitude towards adherence in patients with schizophrenia at dischargeRebecca Schennach-Wolff, Markus Jäger, Florian Seemüller, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 13, 2010
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?Rebecca Schennach-Wolff, Markus Jäger, Michael Obermeier, et al.
Journal of Psychiatric Research|August 25, 2011
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorderRebecca Schennach-Wolff, Sebastian Meyer, Florian Seemüller, et al.
Psychiatric Services (Washington, D.C.)|January 10, 2012
Predictors of relapse in the year after hospital discharge among patients with schizophreniaRebecca Schennach, Michael Obermeier, Sebastian Meyer, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2014
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 4, 2010
Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersR Schennach-Wolff, F Seemüller, M Obermeier, et al.
Pageof 137